KRAS and neoplasm: It has been found using a genome-specific CRISPR-Cas9 knockout screen that specific metabolisms are affected only when KRAS is active on cells, which may have future therapeutic benefits for cancer metabolism in a patient's mutant KRAS tumor, exhibiting some therapeutic application [131].